Britain and America have forged a key commercial pact that will guarantee no tariffs on British pharmaceutical exports entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on pharmaceuticals through the public health system. This pledge guarantees that duties on these key products will stay at nothing for a timeframe of three years.
This development follows recent statements to dramatically increase duties on patented drug products, with potential rates floated up to double the cost.
"This arrangement with the Britain reinforces the global environment for new treatments and brings much-needed fairness to transatlantic medicine commerce," an announcement noted.
Trade Impact
Drugs constitute one of the the United Kingdom's biggest export categories to the US, which is by far the largest destination for major British pharmaceutical firms.
Export figures reveal that in the 12 months to the end of last September, the UK sold drugs totaling over eleven billion pounds to the US. This figure represented a significant portion of total UK exports in that period.
"This deal protects jobs, stimulates funding and paves the way for the UK to become a worldwide center for medical research," a government official stated.
Specific UK Commitments
The agreement includes several key changes from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to double total health service expenditure on medicines from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Industry Background
This agreement follows a long-running row between the sector and the UK government over spending levels and approval rates.
These tensions were exacerbated by arguments that American patients were paying a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several significant pharmaceutical investments in the UK have been paused or scrapped, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its expenditure on drugs had decreased as a proportion of its resources over the previous ten-year period.
